← Back to Insights
March 29, 2023
Authors
David Burda
Topics
Economics Innovation Outcomes
Channels
Blogs

The Real Reason Insurance Companies Won’t Pay for That Breakthrough Drug

The answer to the question posed in the headline is money. Health insurers don’t want to pay for novel drug treatments because they cost too much. I’m sorry, did you think it was for any other reason?

I could end the blog post here, and no one would argue the point. (Some may cheer for other reasons.) But I feel compelled to offer some proof as we’re all about evidenced-based thought leadership here at 4sight Health. We don’t just make shit up. (Our unofficial motto.)

The Center for Connected Medicine provided supporting evidence in a new report. But before we dive into the report’s findings, let’s set the tone.

The general and healthcare trade press has been tearing health insurers apart this year for arbitrarily denying coverage and claims, alleging lack of medical necessity for the care providers give or want to give their patients. Many insurers are using doctors as a cover to do it. Some are using AI-powered technology and algorithms to do it. Others are reflexively hitting the reject claim button.

These stories will get you caught up:

The reason, of course, is money. When insurers take in more and more and pay out less and less, their profits go up and up.

That reason threads its way through this report from the CCM, “Market Access and Reimbursement of Novel Therapeutics: Perspective from payers on managing new and expensive treatments.” The report is based on detailed interviews with eight health insurance company executives, including four execs from provider-sponsored health plans. I guess eight was enough.

Here are a few of the reason-confirming report findings:

  • Seven of the eight described their level of concern over the cost of novel therapeutics as “high.”
  • Seven of the eight cited “limited incremental efficacy over established standard of care” as one of their top challenges regarding the coverage of novel therapeutics. Only two of the eight cited “high out-of-pocket costs for individual patients” as a top challenge.
  • Seven of the eight cited “cost-effectiveness” and “coverage by CMS” as criteria for determining novel therapeutics coverage.
  • Seven of the eight said FDA approval of a novel therapeutic does not automatically trigger benefits coverage of a novel therapeutic.

I get that payers, even those owned by providers whose stated missions are to care for ill or injured patients, don’t want to write a blank check for any new pharmaceutical or biotech treatment that comes along. That would be fiscally irresponsible. At the same time, it’s clear that payers are looking for any reason to say no instead of looking for any evidenced-based reason, medical or financial, to say yes.

Thanks for reading.

About the Author

David Burda

David Burda began covering healthcare in 1983 and hasn’t stopped since. Dave writes this monthly column “Burda on Healthcare,” contributes weekly blog posts, manages our weekly newsletter 4sight Friday, and hosts our weekly Roundup podcast. Dave believes that healthcare is a business like any other business, and customers — patients — are king. If you do what’s right for patients, good business results will follow.

Dave’s personnel experiences with the healthcare system both as a patient and family caregiver have shaped his point of view. It’s also been shaped by covering the industry for 40 years as a reporter and editor. He worked at Modern Healthcare for 25 years, the last 11 as editor.

Prior to Modern Healthcare, he did stints at the American Medical Record Association (now AHIMA) and the American Hospital Association. After Modern Healthcare, he wrote a monthly column for Twin Cities Business explaining healthcare trends to a business audience, and he developed and executed content marketing plans for leading healthcare corporations as the editorial director for healthcare strategies at MSP Communications.

When he’s not reading and writing about healthcare, Dave spends his time riding the trails of DuPage County, IL, on his bike, tending his vegetable garden and daydreaming about being a lobster fisherman in Maine. He lives in Wheaton, IL, with his lovely wife of 40 years and his three children, none of whom want to be journalists or lobster fishermen.

Recent Posts

System Dynamics
Justice Department Sleeping at the Healthcare Fraud Wheel
In a 4sight Health blog post published last month, I said there were only two possible reasons why… Read More
By February 28, 2024
Default Image
Economics
4sight Friday | February 23, 2024
4sight Friday | What FTC Look at GPOs and Drug Distributors Will See | The Story of Year-End… Read More
By February 23, 2024
Outcomes
Podcast: FTC Tries to Open Black Box of Group Purchasing and Drug Distribution 2/22/24
Healthcare group purchasing and drug distribution are controlled by just a handful of GPOs and drug distributors. We… Read More
By February 22, 2024